M. Shah

发表

Gastric cancer--an enigmatic and heterogeneous disease.

J. Ajani, M. Shah, 2010, JAMA.

Does Graded Histologic Response After Neoadjuvant Chemotherapy Predict Survival for Completely Resected Gastric Cancer?

Laura H. Tang, M. Gonen, M. Shah, 2007, Annals of Surgical Oncology.

Targeting the cell cycle: a new approach to cancer therapy.

M. Shah, G. Schwartz, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of intratumoral T cells in biopsies from advanced gastric cancer patients treated with andecaliximab and nivolumab.

M. Shah, E. Van Cutsem, Z. Wainberg, 2019, Journal of Clinical Oncology.

A phase II, open-label, randomized study to evaluate the efficacy and safety of andecaliximab combined with nivolumab versus nivolumab alone in subjects with unresectable or recurrent gastric or gastroesophageal junction adenocarcinoma.

M. Shah, Z. Wainberg, D. Cunningham, 2017, Journal of Clinical Oncology.

Exploratory evaluation of baseline tumor biomarkers and their association with response and survival in patients with previously treated advanced gastric cancer treated with andecaliximab combined with nivolumab versus nivolumab.

M. Shah, E. Van Cutsem, Z. Wainberg, 2019, Journal of Clinical Oncology.

Gastrointestinal Cancer Educational Case Series: Management of Metastatic Adenocarcinoma of Unknown Primary Origin in a Ph+ ALL Survivor

M. Shah, G. Abou-Alfa, M. Lowery, 2011, Journal of gastrointestinal cancer.

A Phase 1 Dose-Escalation Study of Irinotecan in Combination with 17-Allylamino-17-Demethoxygeldanamycin in Patients with Solid Tumors

M. Gonen, K. Manova-Todorova, M. Shah, 2008, Clinical Cancer Research.

Cyclin-dependent kinases as targets for cancer therapy.

M. Shah, G. Schwartz, 2006, Cancer chemotherapy and biological response modifiers.

The relevance of drug sequence in combination chemotherapy.

M. Shah, G. Schwartz, 2000, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

A. Khorana, M. Shah, A. Benson, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gastric cancer epidemiology and risk factors

M. Shah, D. E. Guggenheim, 2013, Journal of surgical oncology.

Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer

P. Bonate, M. Shah, Z. Wainberg, 2013, PloS one.

Hematology and oncology clinical care during the coronavirus disease 2019 pandemic

J. Leonard, M. Shah, K. van Besien, 2020, CA: a cancer journal for clinicians.

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

M. Shah, P. Maliakal, D. Goldenberg, 2015, Clinical Cancer Research.

Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage

A. Sboner, H. Beltran, M. Shah, 2021, Communications biology.

Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer

M. Shah, U. Khan, 2019, Expert opinion on biological therapy.

Is Gastric Cancer Different in Korea and the United States? Impact of Tumor Location on Prognosis

L. Jacks, M. Gonen, M. Shah, 2014, Annals of Surgical Oncology.

Comparison of disease‐specific survival in the United States and Korea after resection for early‐stage node‐negative gastric carcinoma

L. Jacks, M. Gonen, M. Shah, 2013, Journal of surgical oncology.

Comparison of Gastric Cancer Survival Following R0 Resection in the United States and Korea Using an Internationally Validated Nomogram

L. Jacks, M. Gonen, M. Shah, 2010, Annals of surgery.

Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy.

M. Shah, D. Kelsen, D. Ilson, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunotherapy for Gastrointestinal Cancer

M. Shah, 2018 .

Prognostic Role of Lemur Tyrosine Kinase-3 Germline Polymorphisms in Adjuvant Gastric Cancer in Japan and the United States

M. Shah, A. Barzi, H. Lenz, 2013, Molecular Cancer Therapeutics.

Companion Diagnostics and Biomarkers Prognostic Role of Lemur Tyrosine Kinase-3 Germline Polymorphisms in Adjuvant Gastric Cancer in Japan and the United States

M. Shah, A. Barzi, H. Lenz, 2013 .

Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.

M. Rubin, O. Elemento, A. Sboner, 2019, JCO precision oncology.

Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline.

Laura H. Tang, K. Goodman, M. Shah, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Incorporation of biologic therapies in the management of gastroesophageal cancers.

M. Shah, D. Kelsen, M. Jhawer, 2007, Gastrointestinal cancer research : GCR.

A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol

M. Gonen, M. Shah, G. Schwartz, 2010, Cancer Chemotherapy and Pharmacology.

The development of bevacizumab in noncolorectal gastrointestinal malignancies: gastroesophageal, pancreatic, and hepatocellular carcinoma.

M. Shah, 2014, Clinical advances in hematology & oncology : H&O.

Cyclin-Dependent Kinase Inhibitors in Combination Chemotherapy

M. Shah, G. Schwartz, 2005 .

Randomized clinical trials in gastric cancer.

M. Shah, D. Coit, J. Mezhir, 2010, Surgical oncology clinics of North America.

Recent developments in the treatment of gastric carcinoma

M. Shah, 2002, Current oncology reports.

Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma.

S. Groshen, M. Shah, H. Lenz, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Management of advanced gastric cancer

N. Pavlakis, M. Shah, E. Van Cutsem, 2012, Expert review of gastroenterology & hepatology.

Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease.

M. Shah, D. Kelsen, 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

Use of positron emission tomography scan response to guide treatment change for locally advanced gastric cancer: the Memorial Sloan Kettering Cancer Center experience.

Laura H. Tang, M. Bains, M. Shah, 2016, Journal of gastrointestinal oncology.

Treatment of resectable gastric cancer

M. Shah, C. V. D. van de Velde, D. Coit, 2012, Therapeutic advances in gastroenterology.

Uncommon Cancers of the Stomach

M. Shah, Arun Jesudian, F. Schnoll-Sussman, 2012 .

Post-Treatment/Pre-operative PET Response Is Not an Independent Predictor of Outcomes for Patients With Gastric and GEJ Adenocarcinoma

Jonathan M. Hernandez, Laura H. Tang, M. Gonen, 2017, Annals of surgery.

ASCO Clinical Practice Guideline Endorsements and Adaptations.

M. Shah, T. Oliver, M. Chávez-MacGregor, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Risk factors for developing a new venous thromboembolism in ambulatory patients with non‐hematologic malignancies and impact on survival for gastroesophageal malignancies

M. Shah, D. Kelsen, M. Capanu, 2010, Journal of thrombosis and haemostasis : JTH.

Favorable response to second-line atezolizumab and bevacizumab following progression on nivolumab in advanced hepatocellular carcinoma

M. Shah, G. Brar, Omar Gandarilla, 2021, Medicine.

KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma

M. Shah, P. Enzinger, Xiaolong Fu, 2021, Future oncology.

Systemic chemotherapy does not increase the risk of gastrointestinal perforation.

M. Shah, M. Capanu, D. Kelsen, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Cyclin-dependent kinases as targets for cancer therapy.

M. Shah, G. Schwartz, 2006, Cancer chemotherapy and biological response modifiers.

Gastric cancer: The gastric microbiota — bacterial diversity and implications

M. Shah, 2017, Nature Reviews Gastroenterology & Hepatology.

Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response

A. Viale, R. Yantiss, N. Altorki, 2016, Clinical Cancer Research.

Oncologic and Palliative Care in a Global Setting in the Twenty-First Century: The Patient, Family, and Oncologic Health Care Team

M. Shah, 2018, Journal of global oncology.

Total Gastrectomy for Hereditary Diffuse Gastric Cancer at a Single Center: Postsurgical Outcomes in 41 Patients

Laura H. Tang, M. Shah, D. Coit, 2017, Annals of surgery.

Total Gastrectomy for Hereditary Diffuse Gastric Cancer at a Single Center mes in 41 Patients Postsurgical Outco

Laura H. Tang, M. Shah, D. Coit, 2016 .

A Man with Klinefelter’s Syndrome and New Abdominal Distension: A Discussion of Evaluation and Management

M. Shah, G. Abou-Alfa, M. Lowery, 2012, Journal of Gastrointestinal Cancer.

De novo CDH1 mutation in a family presenting with early‐onset diffuse gastric cancer

M. Shah, Z. Stadler, E. Salo-Mullen, 2012, Clinical genetics.

The Role of 18F-FDG PET Imaging in Upper Gastrointestinal Malignancies

M. Shah, T. Dai, E. Popa, 2014, Current Treatment Options in Oncology.

GRP78 promoter polymorphism rs391957 as potential predictor for clinical outcome in gastric and colorectal cancer patients.

M. Shah, H. Lenz, W. Zhang, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

IClinical Trial of the Sequential Combination of Irinotecan Followedby Flavopiridol

C. Cordon-Cardo, M. Gonen, M. Shah, 2005 .

Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.

M. Gonen, M. Shah, N. Kemeny, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of Use of Antibiotics on Response to Immune Checkpoint Inhibitors and Tumor Microenvironment

Doron Betel, M. Shah, A. Roychoudhury, 2021, American journal of clinical oncology.

Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.

M. Shah, J. Tabernero, Yoon-Koo Kang, 2018, The Lancet. Oncology.

Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.

J. Ajani, M. Shah, E. Van Cutsem, 2017, The Lancet. Oncology.

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

Sung-Bae Kim, M. Shah, P. Sunpaweravong, 2021, The Lancet.

Lenvatinib treatment of advanced RAI-refractory differentiated thyroid cancer (DTC): Cytokine and angiogenic factor (CAF) profiling in combination with tumor genetic analysis to identify markers associated with response.

M. Shah, M. Schlumberger, D. Ball, 2012 .

Treatment of Patients With Early-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline Summary.

M. Shah, S. Temin, A. Costas-Chavarri, 2019, Journal of oncology practice.

ASCO Resource-Stratified Guidelines: Methods and Opportunities

M. Shah, S. Temin, J. Gralow, 2018, Journal of global oncology.

Gastrointestinal Cancer Educational Case Series: The History and Management of Complex Cases in GI Oncology. A 72 Year-Old Man with Metastatic Gastric Cancer

M. Shah, G. Abou-Alfa, M. Lowery, 2011, Journal of Gastrointestinal Cancer.

Pertuzumab, trastuzumab, and chemotherapy in HER2-positive gastric/gastroesophageal junction cancer: end-of-study analysis of the JACOB phase III randomized clinical trial

M. Shah, J. Tabernero, Yoon-Koo Kang, 2022, Gastric Cancer.

Randomized phase II study of FOLFOX +/- MET inhibitor, onartuzumab (O), in advanced gastroesophageal adenocarcinoma (GEC).

M. Shah, Yoon-Koo Kang, D. Shames, 2015 .

Final results of a multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with metastatic gastric or gastroesophageal (GEJ) adenocarcinoma (NCI #6447).

M. Shah, G. Schwartz, M. Capanu, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.

Sung-Bae Kim, M. Shah, F. Lordick, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A 71-year-old man with a large cystic pancreatic mass.

M. Shah, G. Abou-Alfa, D. Mukherji, 2012, Gastrointestinal cancer research : GCR.

Survival analysis according to disease subtype in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo in patients (pts) with advanced gastric cancer.

M. Shah, Y. Bang, E. Van Cutsem, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1423MO End-of-study analysis from JACOB: A phase III study of pertuzumab (P) + trastuzumab (H) and chemotherapy (CT) in HER2-positive metastatic gastric or gastro-esophageal junction cancer (mGC/GEJC)

M. Shah, J. Tabernero, A. Ohtsu, 2020 .

Reply: Gastric cancer drug trials—are women second class citizens?

M. Shah, 2014, Nature Reviews Clinical Oncology.

Gastrointestinal cancer: Targeted therapies in gastric cancer—the dawn of a new era

M. Shah, 2014, Nature Reviews Clinical Oncology.

Pharmacokinetic and exposure–response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer

M. Shah, Yoon-Koo Kang, M. Alsina, 2019, Cancer Chemotherapy and Pharmacology.

Pharmacokinetic (PK) and exposure-response (ER) analysis of pertuzumab (P) in patients (pts) with HER2-positive metastatic gastroesophageal junction and gastric cancer (mGEJC/GC).

M. Shah, J. Tabernero, Yoon-Koo Kang, 2018 .

A phase I dose finding study of weekly, sequential docetaxel (Doc) followed by flavopiridol (F) in patients with advanced solid tumors

M. Shah, G. Schwartz, D. Rathkopf, 2004 .

A phase I study of weekly irinotecan (CPT), cisplatin (CIS) and flavopiridol (F).

M. Gonen, M. Shah, G. Schwartz, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized, double-blind, placebo-controlled phase III study of cisplatin plus a fluoropyrimidine with or without ramucirumab as first-line therapy in patients with metastatic gastric or gastroesophogeal junction (GEJ) adenocarcinoma (RAINFALL, NCT02314117).

M. Shah, C. Fuchs, J. Tabernero, 2015 .

Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer

Stuart M. Gardos, M. Shah, B. Denton, 2012, Cancer.

AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC).

M. Shah, E. Van Cutsem, A. Ohtsu, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemotherapy dose intensity predicted by baseline nutrition assessment in gastrointestinal malignancies: A multicentre analysis.

M. Shah, P. Christos, A. Ocean, 2016, European journal of cancer.

Antibody-drug conjugates: can the payload improve activity in HER2 expressing cancers?

M. Shah, 2017, The Lancet. Oncology.

RAINFALL: A randomized, double-blind, placebo-controlled phase III study of cisplatin (Cis) plus capecitabine (Cape) or 5FU with or without ramucirumab (RAM) as first-line therapy in patients with metastatic gastric or gastroesophageal junction (G-GEJ) adenocarcinoma.

J. Lacy, M. Shah, C. Fuchs, 2018 .

Analysis of survival with modified docetaxel, cisplatin, fluorouracil (mDCF), and bevacizumab (BEV) in patients with metastatic gastroesophageal (GE) adenocarcinoma: Results of a phase II clinical trial.

M. Shah, M. Capanu, D. Kelsen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

METGastric: A phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC).

M. Shah, Y. Bang, F. Lordick, 2015 .

Assessment of two dosing schedules of GSK1363089 (GSK089), a dual MET/VEGFR2 inhibitor, in metastatic gastric cancer (GC): Interim results of a multicenter phase II study.

M. Shah, Z. Wainberg, H. Kindler, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.

M. Shah, Yoon-Koo Kang, I. Tan, 2016, The oncologist.

Prognostic significance of human epidermal growth factor-2 (HER2) in advanced gastric cancer: A U.S. and European international collaborative analysis.

M. Shah, Y. Janjigian, S. Al-Batran, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LBA8_PR Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study

M. Shah, P. Sunpaweravong, P. Enzinger, 2020 .

Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response observed in adenocarcinoma.

M. Shah, Y. Janjigian, D. Kelsen, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction – a phase III trial of the German AIO/CAO-V/CAOGI

T. Zander, M. Shah, J. Izbicki, 2017, BMC Cancer.

Reply to M. Mo et al.

M. Shah, A. Garg, L. Herráez-Baranda, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A case report of trastuzumab dose in gastric cancer.

M. Shah, C. Kyi, 2013, Journal of gastrointestinal oncology.

Low molecular weight heparin versus rivaroxaban in the treatment of venous thromboembolism in gastrointestinal malignancies

M. Shah, T. Dai, Sunnie S. Kim, 2018, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

A multicenter phase I study of intravenous administration of reolysin in combination with irinotecan/fluorouracil/leucovorin (FOLFIRI) in patients (pts) with oxaliplatin-refractory/intolerant KRAS-mutant metastatic colorectal cancer (mCRC).

M. Shah, T. Bekaii-Saab, P. Christos, 2013 .

A retrospective observational study on the use of capecitabine in patients with severe renal impairment (GFR <30 mL/min) and end stage renal disease on hemodialysis

M. Shah, K. Jhaveri, S. Latcha, 2012, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

mL / min ) and end stage renal disease on hemodialysis ( GFR < 30 A retrospective observational study on the use of capecitabine in patients with severe renal impairment

M. Shah, K. Jhaveri, S. Latcha, 2012 .

Adapting Hematology and Medical Oncology Clinical Care in the Epicenter of the Covid-19 Pandemic

M. Shah, M. F. Emlen, S. Mayer, 2020, Nejm Catalyst Innovations in Care Delivery.

The germline CDH1 c.48 G>C substitution contributes to cancer predisposition through generation of a pro-invasive mutation.

M. Shah, R. Seruca, Soraia Melo, 2014, Mutation research.

Reply to O.O. Eren et al and S. Mikhail.

M. Shah, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC).

J. Ajani, M. Shah, Yoon-Koo Kang, 2016 .

Phase III KEYNOTE-590 study of chemotherapy + pembrolizumab versus chemotherapy + placebo as first-line therapy for patients (Pts) with advanced esophageal or esophagogastric junction (E/EGJ) cancer.

M. Shah, P. Enzinger, Y. Zhu, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study.

J. Berlin, M. Shah, Sunil Sharma, 2020, The oncologist.

Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study.

M. Shah, E. Van Cutsem, J. Tabernero, 2022, Clinical colorectal cancer.

804 ORAL Evaluation of Plasma VEGFA as a Potential Predictive Pan-tumour Biomarker for Bevacizumab

P. Carmeliet, P. Hegde, G. Jayson, 2011 .

The BRIGHTER trial: A phase III randomized double-blind study of BBI608 + weekly paclitaxel versus placebo (PBO) + weekly paclitaxel in patients (pts) with pretreated advanced gastric and gastro-esophageal junction (GEJ) adenocarcinoma.

M. Shah, Y. Bang, F. Lordick, 2015 .

Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity

M. Shah, D. Kelsen, T. Asmis, 2008, Investigational New Drugs.

Abstract B210: Shed MET (sMET), VEGFA, and sVEGFR2 are markers of foretinib treatment in metastatic gastric cancer patients

M. Shah, D. Bottaro, H. Kallender, 2009 .

Preliminary activity of XL880, a dual MET/VEGFR2 inhibitor, in MET amplified poorly differentiated gastric cancer (PDGC): Interim results of a multicenter phase II study

M. Shah, J. Hecht, Z. Wainberg, 2008 .

Sung-Bae Kim, M. Shah, P. Sunpaweravong, 2021 .

Treatment of liver metastases in patients with neuroendocrine tumors: A National Comprehensive Cancer Network analysis.

E. Nakakura, M. Choti, M. Bloomston, 2013 .

Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer

L. Schwartz, M. Shah, G. Schwartz, 2008, Cancer Chemotherapy and Pharmacology.

Efficacy and safety of everolimus in patients with advanced low- or intermediate-grade pancreatic neuroendocrine tumors previously treated with chemotherapy: RADIANT-3 subgroup analysis.

M. Shah, James C Yao, T. Hobday, 2013 .

Treatment of Pancreatic Neuroendocrine Tumors (pNET) With Everolimus: Improved Progression-Free Survival Compared With Placebo (RADIANT-3)

M. Shah, James C Yao, T. Hobday, 2011 .

Capecitabine in the treatment of esophageal and gastric cancers

M. Shah, E. Popa, 2013, Expert opinion on investigational drugs.

Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial

P. Philip, M. Shah, Y. Bang, 2018, JAMA oncology.

Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database.

D. Sargent, M. Shah, D. Haller, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors

D. Jäger, M. Shah, E. Rasmussen, 2020, Journal for ImmunoTherapy of Cancer.

The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction adenocarcinoma

M. Shah, G. Brar, 2019, Therapeutic advances in gastroenterology.

Small-cell carcinoma of the gastrointestinal tract: a retrospective study of 64 cases

M. Gonen, M. Shah, D. Klimstra, 2004, British Journal of Cancer.

Microtubule Engagement with Taxane Is Altered in Taxane-Resistant Gastric Cancer

M. Shah, P. Giannakakou, Jiaren Zhang, 2020, Clinical Cancer Research.

Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer

J. Ajani, M. Shah, E. Van Cutsem, 2019, Gastric Cancer.

Update on metastatic gastric and esophageal cancers.

M. Shah, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Metastatic Pancreatic Cancer: ASCO Guideline Update.

T. Conroy, P. Philip, M. Shah, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I Dose-Finding Study of Weekly Docetaxel Followed by Flavopiridol for Patients with Advanced Solid Tumors

C. Hudis, M. Shah, G. Schwartz, 2007, Clinical Cancer Research.

Combined Modality Therapy of Esophageal Cancer: Changes in the Standard of Care?

M. Shah, D. Kelsen, 2004, Annals of Surgical Oncology.

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial.

M. Shah, E. Van Cutsem, Yoon-Koo Kang, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Regional differences in advanced gastric cancer: exploratory analyses of the AVAGAST placebo arm

M. Shah, E. Van Cutsem, Yoon-Koo Kang, 2017, Gastric Cancer.

KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.

M. Shah, P. Enzinger, B. Cho, 2019, Future oncology.

Genomic Alterations Observed in Colitis-Associated Cancers Are Distinct From Those Found in Sporadic Colorectal Cancers and Vary by Type of Inflammatory Bowel Disease.

Zachary J. Heins, N. Schultz, R. Yantiss, 2016, Gastroenterology.

Oesophageal cancer

M. Shah, F. Lordick, R. Fitzgerald, 2017, Nature Reviews Disease Primers.

A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus

D. Levine, J. Boyd, M. Shah, 2011, Cancer.

Chapter 42 – Gastric and Gastroesophageal Adenocarcinoma

M. Shah, D. Kelsen, 2008 .

MET Expression and Amplification in Patients with Localized Gastric Cancer

Laura H. Tang, S. Jhanwar, M. Shah, 2011, Cancer Epidemiology, Biomarkers & Prevention.

Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution.

M. Rubin, O. Elemento, A. Sboner, 2019, JCO precision oncology.

Advanced gastric cancer--slow but steady progress.

M. Shah, D. Kelsen, D. Power, 2010, Cancer treatment reviews.

Early‐onset Colorectal Cancer is Distinct From Traditional Colorectal Cancer

R. Yantiss, M. Shah, J. Abelson, 2017, Clinical colorectal cancer.

Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study

Sung-Bae Kim, J. Lunceford, M. Shah, 2019, JAMA oncology.

Cell cycle-mediated drug resistance: an emerging concept in cancer therapy.

M. Shah, G. Schwartz, G K Schwartz, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

An individual coding polymorphism and the haplotype of the SPARC gene predict gastric cancer recurrence

M. Shah, H. Lenz, W. Zhang, 2012, The Pharmacogenomics Journal.

Clinical Screening for COVID-19 in Asymptomatic Patients With Cancer

Evan T. Sholle, M. Shah, P. Christos, 2020, JAMA network open.

Multicenter, randomized phase II study of neoadjuvant pembrolizumab plus chemotherapy and chemoradiotherapy in esophageal adenocarcinoma (EAC).

N. Sanfilippo, R. Yantiss, N. Altorki, 2021 .

Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.

Laura H. Tang, M. Shah, Y. Janjigian, 2011, Archives of pathology & laboratory medicine.

Germline polymorphisms in genes involved in the CD44 signaling pathway are associated with clinical outcome in localized gastric adenocarcinoma

Laura H. Tang, M. Shah, H. Lenz, 2011, International journal of cancer.

A multicenter, phase II study of Bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma

Laura H. Tang, M. Shah, M. Capanu, 2011, Investigational New Drugs.

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

L. Schwartz, M. Shah, N. Kemeny, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of life at the end of life: trends in patients with metastatic prostate cancer.

A. Neugut, P. Maciejewski, M. Shah, 2002, Urology.

Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-181 study.

Sung-Bae Kim, M. Shah, P. Enzinger, 2019, Journal of Clinical Oncology.

Drg1 Expression in 131 Colorectal Liver Metastases: Correlation with Clinical Variables and Patient Outcomes

C. Cordon-Cardo, M. Gonen, M. Shah, 2005, Clinical Cancer Research.

Redefining Intermediate-Stage HCC Treatment in the Era of Immune Therapies.

A. Kesselman, M. Shah, G. Brar, 2021, JCO oncology practice.

A Phase I Clinical Trial of the Sequential Combination of Irinotecan Followed by Flavopiridol

C. Cordon-Cardo, M. Gonen, M. Shah, 2005, Clinical Cancer Research.

Phase IDose-Finding Study of Weekly Docetaxel Followed by Flavopiridol for Patients with Advanced

C. Hudis, M. Shah, G. Schwartz, 2007 .

A Comparison of Homogenization vs. Enzymatic Lysis for Microbiome Profiling in Clinical Endoscopic Biopsy Tissue Samples

Chao Zhang, M. Shah, Prateek Sharma, 2019, Front. Microbiol..

APhase 1 Dose-Escalation Study of Irinotecan in Combination with 17-Allylamino-17-Demethoxygeldanamycin in Patients with Solid Tumors

M. Gonen, M. Shah, R. Maki, 2008 .

Met, IGF1R, and Other New Targets in Upper GI Malignancies

M. Shah, E. Popa, 2013, Current Treatment Options in Oncology.

Cancers of the Esophagus and Small Bowel, Precancerous States of the Large Bowel, and Gastrointestinal Stromal Tumors

M. Shah, K. Zukotynski, E. Smyth, 2013 .

A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer.

B. Brenner, Laura H. Tang, M. Gonen, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies

C. Tournigand, J. Ajani, M. Shah, 2022, Cancers.

Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1)

J. Ajani, M. Shah, G. Bodoky, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome

O. Elemento, M. Pittman, P. Philip, 2020, Clinical Cancer Research.

Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors

M. Shah, R. Bies, K. Attwood, 2020, Cancer.

Upper gastrointestinal cancer predisposition syndromes.

M. Shah, R. Kurtz, 2010, Hematology/oncology clinics of North America.

Chemotherapy Use, End-of-Life Care, and Costs of Care Among Patients Diagnosed With Stage IV Pancreatic Cancer.

P. Maciejewski, M. Shah, H. Prigerson, 2018, Journal of pain and symptom management.

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial.

J. Lacy, M. Shah, C. Fuchs, 2019, The Lancet. Oncology.

Stage-Stratified Prognosis of Signet Ring Cell Histology in Patients Undergoing Curative Resection for Gastric Adenocarcinoma

Mithat Gonen, Deborah Kuk, Laura H. Tang, 2014, Annals of Surgical Oncology.

Imatinib overrides taxane resistance by selective inhibition of novel CLIP1 variant obstructing the microtubule pore

Neel S. Madhukar, O. Elemento, M. Shah, 2019 .

Anaplastic thyroid cancer

M. Shah, R. Ranganath, A. R. Shah, 2015, Current opinion in endocrinology, diabetes, and obesity.

Molecular Classification of Gastric Cancer: A New Paradigm

Laura H. Tang, R. Khanin, M. Shah, 2011, Clinical Cancer Research.

The Gastric Cancers: Targeted for Personalized Medicine

M. Shah, T. Wang, 2013 .

Perineural Invasion After Preoperative Chemotherapy Predicts Poor Survival in Patients With Locally Advanced Gastric Cancer: Gene Expression Analysis With Pathologic Validation

L. Qin, Laura H. Tang, M. Gonen, 2009, American journal of clinical oncology.

Treatment of Patients With Early-Stage Colorectal Cancer: ASCO Resource-Stratified Guideline

R. Yantiss, M. Stern, C. Hamashima, 2019, Journal of global oncology.

Associations between Anxiety, Poor Prognosis, and Accurate Understanding of Scan Results among Advanced Cancer Patients.

V. Reyna, P. Maciejewski, M. Shah, 2019, Journal of palliative medicine.

A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane

J. Ajani, C. Bokemeyer, M. Shah, 2006, Investigational New Drugs.

Role of ¹⁸F 2-fluoro-2-deoxyglucose positron emission tomography in upper gastrointestinal malignancies.

Manish A Shah, M. Shah, E. Smyth, 2011, World journal of gastroenterology.

MetGastric: A randomized phase III study of onartuzumab (MetMAb) in combination with mFOLFOX6 in patients with metastatic HER2-negative and MET-positive adenocarcinoma of the stomach or gastroesophageal junction.

M. Shah, Y. Bang, F. Lordick, 2013 .

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.

M. Shah, E. Van Cutsem, Yoon-Koo Kang, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma

Laura H. Tang, M. Gönen, M. Gonen, 2011, British Journal of Cancer.

Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.

M. Shah, M. Capanu, D. Kelsen, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.

L. Schwartz, M. Shah, G. Schwartz, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Future Directions in Improving Outcomes for Patients with Gastric and Esophageal Cancer.

M. Shah, 2017, Hematology/oncology clinics of North America.

Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis.

Laura H. Tang, M. Shah, Y. Janjigian, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of preoperative chemotherapy with irinotecan(CPT) and cisplatin(CIS) for gastric cancer(NCI 5917): FDG-PET/CT predicts patient outcome

Laura H. Tang, M. Shah, D. Coit, 2007 .

Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update.

A. Khorana, P. Philip, M. Shah, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of low abundance microbiome in clinical samples using whole genome sequencing

Doron Betel, Chao Zhang, Nikolaus Schultz, 2015, Genome Biology.

Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

A. Khorana, P. Philip, M. Shah, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tobacco Use Is Associated with Increased Recurrence and Death from Gastric Cancer

M. Shah, D. Coit, Y. Janjigian, 2012, Annals of Surgical Oncology.

Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer

V. Rusch, Laura H. Tang, M. Bains, 2012, Cancer.

Treatment of metastatic esophagus and gastric cancer.

M. Shah, G. Schwartz, 2004, Seminars in oncology.

Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.

M. Shah, Y. Janjigian, M. Capanu, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Positive Peritoneal Cytology in Patients with Gastric Cancer: Natural History and Outcome of 291 Patients

L. Jacks, M. Shah, D. Coit, 2010, Annals of Surgical Oncology.

Positive Peritoneal Cytology in Patients with Gastric Cancer: Natural History and Outcome of 291 Patients

L. Jacks, M. Shah, D. Coit, 2011, Indian journal of surgical oncology.

IMMU-132, an SN-38 antibody-drug conjugate (ADC) targeting Τrop-2, as a novel platform for the therapy of diverse metastatic solid cancers: Clinical results.

M. Shah, W. Messersmith, P. Maliakal, 2014 .

Outcome of Patients with Known Metastatic Gastric Cancer Undergoing Resection with Therapeutic Intent

Laura H. Tang, M. Shah, D. Bentrem, 2007, Annals of Surgical Oncology.

Positive Peritoneal Cytology in Gastric Cancer

M. Shah, D. Coit, J. Mezhir, 2011, Annals of Surgical Oncology.

Management of hyperglycemia in patients with metastatic pancreatic cancer receiving UCN-01 and fluorouracil.

M. Gonen, M. Shah, G. Abou-Alfa, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial

M. Shah, Y. Bang, F. Lordick, 2017, JAMA oncology.

HELOISE: Phase IIIb Randomized Multicenter Study Comparing Standard-of-Care and Higher-Dose Trastuzumab Regimens Combined With Chemotherapy as First-Line Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma.

M. Shah, Y. Bang, J. Tabernero, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival

M. Shah, E. Van Cutsem, Z. Wainberg, 2021, Journal for ImmunoTherapy of Cancer.

A Woman with Remotely Treated Pancreas Cancer and New Abdominal Pain: A Discussion of Evaluation and Management

M. Shah, G. Abou-Alfa, M. Lowery, 2011, Journal of gastrointestinal cancer.

Pembrolizumab in previously treated metastatic esophageal cancer: Longer term follow-up from the phase 2 KEYNOTE-180 Study.

Sung-Bae Kim, M. Shah, F. Lordick, 2019, Journal of Clinical Oncology.

Early Detection for Colorectal Cancer: ASCO Resource-Stratified Guideline

R. Yantiss, M. Stern, C. Hamashima, 2019, Journal of global oncology.

Conditional Probability of Survival Nomogram for 1-, 2-, and 3-Year Survivors After an R0 Resection for Gastric Cancer

M. Kattan, M. Gonen, M. Shah, 2013, Annals of Surgical Oncology.

The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.

M. Shah, Y. Bang, F. Lordick, 2018 .

The Gastric Microbiome and Its Influence on Gastric Carcinogenesis: Current Knowledge and Ongoing Research.

M. Shah, Chao-peng Zhang, D. Betel, 2017, Hematology/oncology clinics of North America.

A 67-Year-Old Woman with BRCA 1 Mutation Associated with Pancreatic Adenocarcinoma

M. Shah, A. Gabizon, M. Lowery, 2011, Journal of gastrointestinal cancer.

Being present: oncologists' role in promoting advanced cancer patients' illness understanding

P. Maciejewski, M. Shah, H. Prigerson, 2018, Cancer medicine.

How should we care for elderly cancer patients?

M. Shah, J. Feilchenfeldt, 2009, Oncology.

Role of Repeat Staging Laparoscopy in Locoregionally Advanced Gastric or Gastroesophageal Cancer after Neoadjuvant Therapy

M. Gönen, M. Shah, D. Coit, 2013, Annals of Surgical Oncology.

T. Zander, M. Shah, J. Izbicki, 2017, BMC Cancer.

Single nucleotide polymorphisms in AREG and EREG are prognostic biomarkers in locally advanced gastric cancer patients after surgery with curative intent

M. Shah, A. Barzi, H. Lenz, 2014, Pharmacogenetics and genomics.

Gastric cancer: An update

M. Shah, 2006, Current oncology reports.

Toward a Treatment Sequencing Strategy: A Systematic Review of Treatment Regimens in Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma

M. Shah, E. Van Cutsem, Z. Wainberg, 2021, The oncologist.

Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management?

K. Goodman, M. Shah, J. Posey, 2019, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

A prospective evaluation of the utility of 2‐deoxy‐2‐[18F]fluoro‐D‐glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer

M. Shah, D. Coit, M. Capanu, 2012, Cancer.

Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer

N. Schultz, M. Berger, M. Shah, 2018, Gastric Cancer.

Template for Reporting Results of HER2 (ERBB2) Biomarker Testing of Specimens From Patients With Adenocarcinoma of the Stomach or Esophagogastric Junction.

S. Kakar, Laura H. Tang, M. Troxell, 2015, Archives of pathology & laboratory medicine.

COVID-19 Severity and Outcomes in Patients With Cancer: A Matched Cohort Study.

M. Shah, E. Reshetnyak, O. Soroka, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of CTCAE v4 grading of hypertension on reported toxicity in advanced cancer patients receiving vascular endothelial growth factor (VEGF)-targeting agents.

H. Beltran, M. Shah, S. Tagawa, 2013 .

Phase I study of GS-5745 alone and in combination with chemotherapy in patients with advanced solid tumors.

M. Shah, Z. Wainberg, J. Bendell, 2015 .

Effect of post-discontinuation therapy (PDT) on survival in metastatic gastric-gastroesophageal junction (G-GEJ) adenocarcinoma patients from the RAINFALL trial: An exploratory analysis.

J. Lacy, M. Shah, C. Fuchs, 2018 .

Endoscopic ultrasound can improve the selection for laparoscopy in patients with localized gastric cancer.

M. Shah, D. Coit, M. Brennan, 2009, Journal of the American College of Surgeons.

Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative.

R. Labianca, J. Meyerhardt, M. Shah, 2020, European Journal of Cancer.

A phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of andecaliximab combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma (GAMMA-1).

J. Ajani, M. Shah, G. Bodoky, 2019, Journal of Clinical Oncology.

Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study

J. Berlin, M. Shah, H. Lenz, 2018, Clinical Cancer Research.

CanStem303C trial: A phase III study of napabucasin (BBI-608) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic colorectal cancer (mCRC).

M. Shah, A. Grothey, R. Xu, 2017 .

E-cadherin gene alterations in gastric cancers in different ethnic populations.

Laura H. Tang, M. Shah, M. Steinberg, 2008, Ethnicity & disease.

Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response and protracted stable disease observed in adenocarcinoma.

M. Shah, Y. Janjigian, M. Capanu, 2011, Journal of Clinical Oncology.

Phase II trial of preoperative bevacizumab (Bev), irinotecan (I), cisplatin (C), and radiation (RT) in esophageal adenocarcinoma: Preliminary safety analysis.

V. Rusch, M. Bains, K. Goodman, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development of the Oncolo-GIST ("Giving Information Strategically & Transparently") Intervention Manual for Oncologist Skills Training in Advanced Cancer Prognostic Information Communication.

V. Reyna, P. Maciejewski, M. Shah, 2020, Journal of pain and symptom management.

Phase II study of zolbetuximab plus pembrolizumab in claudin 18.2: Positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)—ILUSTRO Cohort 3.

J. Ajani, M. Shah, Y. Bang, 2021 .

Phase 2 study of zolbetuximab plus mFOLFOX6 in claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ): ILUSTRO cohort 2.

M. Shah, Y. Bang, J. Raizer, 2022, Journal of Clinical Oncology.

KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.

M. Shah, Y. Bang, C. Fuchs, 2017 .

A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GS-5745 combined with mFOLFOX6 as first-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma.

M. Shah, Z. Wainberg, J. Bendell, 2017 .

Cyclin-dependent kinases as targets for cancer therapy.

M. Shah, G. Schwartz, 2003, Cancer chemotherapy and biological response modifiers.

Chemoradiation in oesophageal cancer.

M. Shah, Tong Dai, 2015, Best practice & research. Clinical gastroenterology.

Chemotherapy Use , Performance Status , and Quality of Life Near Death Chemotherapy at the End of Life

A. Neugut, P. Maciejewski, M. Shah, 2015 .

Evaluation of PET response to neoadjuvant therapy for patients with gastric and GEJ adenocarcinoma.

Jonathan M. Hernandez, Laura H. Tang, M. Gonen, 2014 .

CLO20-054: A Phase 2 Trial of Nivolumab and Temozolomide in Advanced Neuroendocrine Tumors (NETs): Interim Efficacy Analysis

M. Shah, C. Verschraegen, G. Otterson, 2020 .

Safety and efficacy of panitumumab following cetuximab: retrospective review of the Memorial Sloan-Kettering experience

M. Shah, N. Kemeny, D. Power, 2010, Investigational New Drugs.

Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors

M. Gonen, M. Shah, G. Schwartz, 2009, Clinical Cancer Research.

Phase II Trial of Cetuximab Plus Cisplatin and Irinotecan in Patients With Cisplatin and Irinotecan-refractory Metastatic Esophagogastric Cancer

M. Shah, Y. Janjigian, G. Ku, 2014, American journal of clinical oncology.

Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase 3 KEYNOTE-181 study.

Sung-Bae Kim, M. Shah, P. Enzinger, 2019, Journal of Clinical Oncology.

A 72-year-old man with duodenal adenocarcinoma.

David P Kelsen, Ali Shamseddine, Fady Geara, 2012, Gastrointestinal cancer research : GCR.

Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic colorectal cancer (mCRC).

J. Berlin, M. Shah, E. Baloglu, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

SKYSCRAPER-07: A phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab in patients with unresectable ESCC who have not progressed following definitive concurrent chemoradiotherapy.

K. Goodman, M. Shah, B. Cho, 2022, Journal of Clinical Oncology.

Long COVID in Cancer

M. Shah, M. Rajan, M. Hidalgo, 2023, American journal of clinical oncology.

Optimizing Therapies in the Perioperative Management of Gastric Cancer

M. Shah, U. Khan, 2019, Current Treatment Options in Oncology.

A Phase II Study of Flavopiridol (Alvocidib) in Combination with Docetaxel in Refractory, Metastatic Pancreatic Cancer

Gary K. Schwartz, Mithat Gonen, Robert A. Lefkowitz, 2009, Pancreatology.

Immunotherapy in Patients With Locally Advanced Esophageal Carcinoma: ASCO Treatment of Locally Advanced Esophageal Carcinoma Guideline Rapid Recommendation Update.

M. Shah, W. Hofstetter, E. Kennedy, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Drg 1 Expression in 131 Colorectal LiverMetastases : Correlation with ClinicalVariables and Patient Outcomes

C. Cordon-Cardo, M. Gonen, M. Shah, 2005 .

O-7 FOLFIRI ± napabucasin in patients with previously treated metastatic colorectal cancer: Overall survival results from the phase 3 CanStem303C study

M. Shah, J. Tabernero, M. Fakih, 2021, Annals of Oncology.

Comparative effectiveness of treatment modalities in non-metastatic gastric adenocarcinoma: a propensity score matching analysis of the National Cancer Database

M. Shah, A. Barzi, Dongyun Yang, 2020, BMJ open gastroenterology.

Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach

R. Yantiss, M. Shah, J. Sparano, 2014, Investigational New Drugs.

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.

M. Shah, E. Van Cutsem, Yoon-Koo Kang, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II trial of IMMU-132 (isactuzumab govitecan), an anti-Trop-2-SN-38 antibody drug conjugate (ADC): Results in patients with metastatic gastrointestinal (GI) cancers.

A. Bardia, M. Shah, W. Messersmith, 2015 .

T. Zander, M. Shah, J. Izbicki, 2017, BMC Cancer.

Palliative Chemotherapy or Radiation and Prognostic Understanding among Advanced Cancer Patients: The Role of Perceived Treatment Intent.

V. Reyna, P. Maciejewski, M. Shah, 2020, Journal of Palliative Medicine.

First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590 study.

Sung-Bae Kim, M. Shah, P. Sunpaweravong, 2022, Journal of Clinical Oncology.

Volumetric 3D CT analysis - an early predictor of response to therapy

Minita Shah, L. Schwartz, M. Shah, 2007 .

Phase II trial of bevacizumab, irinotecan, cisplatin, and radiation as preoperative therapy in esophageal adenocarcinoma.

V. Rusch, M. Bains, K. Goodman, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II Study of Flavopiridol (Alvocidib) in Combination with Docetaxel in Refractory, Metastatic Pancreatic Cancer

M. Gonen, M. Shah, G. Schwartz, 2009, Pancreatology.

Therapy of gastrointestinal malignancies with an anti-Trop-2-SN-38 antibody drug conjugate (ADC) (sacituzumab govitecan): Phase I/II clinical experience.

J. Berlin, A. Bardia, M. Shah, 2015 .

Phase I Study of Flavopiridol with Oxaliplatin and Fluorouracil/Leucovorin in Advanced Solid Tumors

M. Gonen, M. Shah, G. Schwartz, 2009, Clinical Cancer Research.

Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET): Results of a planned interim efficacy analysis.

Helen X. Chen, M. Shah, H. Lenz, 2012 .

Being present: oncologists' role in promoting advanced cancer patients' illness understanding

P. Maciejewski, M. Shah, H. Prigerson, 2018, Cancer medicine.

Template for Reporting Results of HER2 (ERBB2) Biomarker Testing of Specimens From Patients With Adenocarcinoma of the Stomach or Esophagogastric Junction.

S. Kakar, Laura H. Tang, M. Troxell, 2015, Archives of pathology & laboratory medicine.

The Quality of Quality-of-Life and Cost-Effectiveness Analyses.

Derek G Power, David P Kelsen, Manish A Shah, 2008, Gastrointestinal cancer research : GCR.